SKINVIVE vs Profhilo: Differences, Cost, Results & Suitability
SKINVIVE by JUVÉDERM and Profhilo are both injectable hyaluronic acid treatments used in aesthetic medicine, but they differ in formulation, clinical evidence and treatment protocols.
SKINVIVE is a cross-linked hyaluronic acid dermal filler with defined US FDA indications for improving cheek skin smoothness and reducing neck lines. Profhilo contains stabilised hybrid cooperative complexes of hyaluronic acid and has been studied for aspects of skin quality, including hydration and elasticity.
Their treatment objectives may overlap, but neither is primarily intended to replace structural facial volume or provide surgical-type lifting.
This SKINVIVE vs Profhilo guide compares their differences, clinical results, treatment schedules, longevity, cost in India, safety and suitability to help patients make an informed decision.
SKINVIVE vs Profhilo: Key Differences at a Glance
The following table summarises the most relevant differences between the two injectable treatments.
Parameter | SKINVIVE by JUVÉDERM | Profhilo |
Formulation | Cross-linked hyaluronic acid injectable gel containing lidocaine | Stabilised hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid |
Product classification | Hyaluronic acid dermal filler | Injectable hyaluronic acid medical device used for skin-quality applications |
Principal clinical focus | Improving skin smoothness in specified treatment areas | Addressing aspects of skin quality evaluated in clinical studies |
Regulatory indication / investigated applications | US FDA indications for cheek skin smoothness and neck-line reduction in adults over 21 | Facial and other skin-quality applications have been studied; permitted uses depend on local product authorisation |
Injection approach | Intradermal for cheeks; intradermal and/or subdermal for neck under US labelling | Product-specific technique; the Bio Aesthetic Point protocol is commonly used for facial treatment |
Initial treatment course | May involve one treatment, with an additional touch-up if indicated | Commonly two facial sessions approximately four weeks apart |
Studied outcomes | Cheek skin smoothness and neck-line severity under separate indications | Hydration, elasticity-related measures, wrinkles and other skin-quality parameters |
Duration evidence | Original cheek-smoothness response demonstrated through six months; separate neck study also reports six-month outcomes | Duration depends on the study, formulation, measured endpoint and follow-up period |
Structural volume restoration | Not primarily intended for structural augmentation | Not primarily intended for structural augmentation |
Published clinic session price | ₹25,000–₹35,000 | Starting at ₹40,000 |
Illustrative initial-course cost | ₹25,000–₹35,000 if one session is sufficient | Approximately ₹80,000 for a commonly used two-session course |
Evidence limitation | Cheek and neck study outcomes cannot automatically be generalised to every skin-quality concern | Studies differ in design, treatment areas and measured outcomes; some findings are less conclusive than others |
Clinical qualification: Regulatory indications listed for SKINVIVE refer specifically to the United States. They should not be interpreted as establishing identical Indian authorisation. Profhilo’s clinical applications must likewise be considered against the relevant local product documentation. The quoted prices are those currently displayed on The Face Clinic’s website and should be reconfirmed before treatment.
The essential distinction: SKINVIVE has defined regulatory evidence for specified skin-smoothness and neck-line outcomes. Profhilo has been investigated across several skin-quality measures. These are different evidence frameworks—not proof that either product is universally superior.
What Is the Difference Between SKINVIVE and Profhilo?
Whether comparing SKINVIVE vs Profhilo or searching for Profhilo vs SKINVIVE, the clinically important differences involve their hyaluronic acid formulations, administration protocols and supporting evidence.
Both contain hyaluronic acid, but they should not be treated as interchangeable injectables simply because they share this ingredient.
Formulation and Hyaluronic Acid Technology
SKINVIVE by JUVÉDERM
SKINVIVE is a cross-linked hyaluronic acid injectable gel containing lidocaine.
Cross-linking modifies the physical characteristics of the HA gel and influences how it behaves within tissue.
SKINVIVE belongs to the dermal filler category. However, its specified skin-smoothness applications differ from the principal purpose of conventional volumising fillers used to create structural projection or restore facial volume.
For its original US-approved cheek indication, SKINVIVE is administered intradermally to improve skin smoothness.
It would therefore be inaccurate to describe SKINVIVE as categorically not a filler, or to suggest that it produces absolutely no volume-related tissue effect.
Its intended clinical objective differs from structural augmentation.
International readers may also encounter the name JUVÉDERM VOLITE. The FDA’s original SKINVIVE documentation identifies JUVÉDERM VOLITE as the product’s name in markets outside the United States, while describing market-specific formulations and labelling. The exact product supplied should always be confirmed in the relevant country.
For product-specific information, see SKINVIVE treatment in Delhi.
Profhilo
Profhilo contains stabilised hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid, produced using IBSA’s NAHYCO technology.
Unlike conventional chemically cross-linked HA fillers, the hybrid complexes are produced through a thermal process without chemical cross-linking agents.
The standard Profhilo formulation investigated in facial clinical research contains 64 mg of hyaluronic acid in 2 mL, comprising 32 mg each of high- and low-molecular-weight HA.
Profhilo is frequently described as a bioremodelling treatment.
However, this terminology should not be interpreted as proof of significant structural lifting or equivalent correction of descended facial tissues.
Published studies have examined outcomes including hydration, transepidermal water loss, elasticity and wrinkle severity.
The findings vary by study and clinical endpoint.
Further treatment information is available on the dedicated Profhilo treatment in Delhi page.
Injection Approach and Treatment Purpose
The products are administered using different product-specific techniques.
Under its current US labelling, SKINVIVE is administered intradermally for cheek skin smoothness. The expanded neck indication permits intradermal and/or subdermal placement.
Profhilo facial treatment commonly uses the Bio Aesthetic Point, or BAP, technique, involving injections at selected anatomical points.
In a published facial study involving Chinese women, Profhilo was administered at five points on each side of the face. Participants received two treatments four weeks apart.
The protocol is described in the published Profhilo study in Asian patients.
This does not establish one universal injection pattern for every anatomical area or formulation.
Importantly, the number of injection points does not independently determine which treatment is safer, more effective or more comfortable.
Injection technique must be considered alongside facial anatomy, product characteristics, intended outcome and practitioner expertise.
Which Skin Concerns May Each Treatment Address?
Patients often describe concerns using broad expressions such as dehydrated skin, tired-looking skin, loss of firmness or facial ageing.
These descriptions may reflect different underlying changes.
Skin hydration, surface smoothness, elasticity, structural volume and tissue descent are related but distinct clinical considerations.
Skin concern | SKINVIVE | Profhilo |
Uneven cheek skin smoothness | Directly relevant to its original US-approved indication | Texture may be considered within broader skin-quality applications |
Reduced skin hydration | Hydration-related outcomes have been investigated | Hydration has been evaluated in published studies |
Changes in elasticity | Not the primary endpoint of its original cheek approval | Elasticity-related outcomes have been studied, with varying strength of evidence |
Mild changes in firmness | Not established as a structural lifting treatment | May be considered for selected skin-quality concerns; lifting should not be assumed |
Neck lines | Separate US FDA indication approved in June 2026 | Neck skin quality has been investigated, subject to formulation and applicable product information |
Hollow cheeks or structural volume loss | Not primarily intended for structural volume restoration | Not primarily intended for structural volume restoration |
Significant facial sagging | Does not replace structural lifting | Does not replace structural lifting |
Pigmentation or melasma | Not a primary pigment-correction treatment | Not a primary pigment-correction treatment |
Skin quality is not the same as structural facial correction
An improvement in skin smoothness does not necessarily mean that underlying facial volume has been restored.
Similarly, an improvement in measured elasticity does not automatically establish clinically meaningful lifting of descended facial tissues.
Some Profhilo studies have measured facial-volume-loss scores. However, improvement on a particular assessment scale is not equivalent to demonstrating the structural augmentation expected from conventional volumising fillers.
A patient may also experience more than one concern simultaneously.
For example, facial skin may appear less hydrated while the cheeks show deeper volume loss.
Those findings require separate clinical consideration rather than an assumption that one injectable will correct every contributing factor.
For a broader explanation of related treatment categories, see skin booster treatment options.
SKINVIVE vs Profhilo: Sessions and Treatment Schedule
The number of appointments is an important practical consideration when comparing injectable skin-quality treatments.
However, a shorter initial course does not necessarily establish greater effectiveness, longer-lasting results or better suitability.
How Many SKINVIVE Sessions Are Usually Required?
SKINVIVE may involve one initial treatment, with an additional touch-up considered according to the applicable protocol and individual assessment.
In the original US cheek-smoothness study, an optional touch-up was permitted approximately one month after initial treatment.
Further treatment requirements depend on the anatomical area, product quantity, treatment objective and individual response.
One session should not be interpreted as a guarantee of a particular result or duration.
How Many Profhilo Sessions Are Usually Required?
A commonly used facial Profhilo protocol involves two sessions approximately four weeks apart.
This schedule has also been used in published facial research.
However, treatment requirements can vary according to the formulation, anatomical area, skin characteristics and response.
A two-session starting protocol does not mean that every patient requires precisely two appointments or that additional treatment will never be necessary.
Treatment Timeline, Recovery and Follow-Up
The following table provides a practical comparison of the initial treatment commitment.
Practical consideration | SKINVIVE | Profhilo |
Initial appointments | One may be sufficient; touch-up when indicated | Commonly two |
Initial treatment spacing | Optional touch-up according to the product-specific protocol | Approximately four weeks between sessions |
Assessment in cited research | Original cheek study evaluated its primary endpoint one month after initial treatment or optional touch-up | Cited facial study included follow-up through Week 12 |
Immediately after treatment | Redness, swelling, tenderness, bruising or temporary bumps may occur | Similar injection-site reactions and temporary raised areas may occur |
Maintenance | Based on individual assessment | Based on individual assessment |
Both procedures involve injections, and visible reactions can occur.
Profhilo may produce temporary elevations at selected injection points. SKINVIVE can also produce injection-site bumps or swelling.
The severity and duration of these reactions vary.
Patients should therefore not assume that either procedure has absolutely no downtime.
The treating practitioner should explain the expected recovery, relevant precautions and circumstances requiring medical attention.
Treatment schedule and treatment longevity are different considerations. A two-session protocol describes how treatment is administered; it does not establish how long every clinical benefit persists.
SKINVIVE vs Profhilo Results: What Does the Evidence Show?
Both treatments have published clinical evidence.
However, their studies do not consistently evaluate identical outcomes, follow equivalent treatment protocols or involve comparable patient populations.
Understanding these differences is essential when interpreting treatment results.
What Has Been Demonstrated for SKINVIVE?
SKINVIVE received its original US FDA approval for improving cheek skin smoothness in adults over 21 on May 11, 2023.
The supporting pivotal study involved 209 randomised participants.
The trial compared SKINVIVE treatment with an untreated control group using a defined cheek-smoothness assessment.
What did the original study find?
In the pivotal study:
- 57.9% of participants in the SKINVIVE treatment group achieved the predefined cheek-smoothness response threshold at one month after initial treatment or optional touch-up.
- 4.5% of participants in the untreated control group met the same threshold.
- 55.6% of treated participants with evaluable data at six months continued to meet the predefined response threshold.
The assessment used the Allergan Cheek Smoothness Scale, with response defined as an improvement of at least one grade.
The one-month percentages are based on the study’s imputed primary analysis, whereas the six-month figure is based on observed data from evaluable treated participants. They should not be treated as identical analysis populations.
These findings establish improvement in a specified clinical endpoint.
They do not mean that 57.9% of patients experienced every possible skin-quality benefit, nor that all patients maintained identical results over six months.
The complete findings are documented in the original FDA cheek-smoothness clinical study.
What changed in June 2026?
On June 11, 2026, the US FDA expanded SKINVIVE’s indication to include reducing neck lines to improve neck appearance in adults over 21.
This is a separate indication supported by a separate clinical study.
In the neck study:
- 74.8% of participants in the SKINVIVE treatment group achieved the predefined neck-line response threshold at one month after initial treatment or optional touch-up.
- 16.1% of untreated controls met that threshold.
- 66.0% of treated participants with evaluable data at six months continued to demonstrate the defined improvement.
The primary endpoint involved at least a one-grade improvement on the study’s Allergan Transverse Neck Lines Scale. The one-month results used an imputed analysis; the six-month percentage was based on observed data.
The findings support the defined neck-line indication. They should not be described as proof of general neck lifting or applied to unrelated skin-quality outcomes.
The regulatory decision is documented in the FDA’s June 2026 SKINVIVE approval record.
These are US regulatory decisions. The applicable indications and instructions for products supplied in India must be verified independently.
What Has Been Demonstrated for Profhilo?
Profhilo has been investigated for several aspects of skin quality, including hydration, elasticity-related measures, skin density and wrinkle severity.
The available research suggests potential benefits across selected outcomes, but the strength of evidence is not uniform.
Evidence from a 2026 systematic review
A systematic review published in 2026 examined nine studies involving 278 participants treated with Profhilo or Profhilo Body.
Across the included research, the authors identified statistically significant changes or trends towards improvement in several skin-quality parameters.
These included hydration, elasticity-related measures, skin density and certain laxity-related outcomes.
However, the studies differed in design, anatomical region, product formulation and follow-up duration.
Findings involving Profhilo Body cannot automatically be generalised to standard facial Profhilo protocols.
Three authors were employees of IBSA, the manufacturer. This affiliation is relevant when assessing the independence of the review.
The publication is available in the 2026 systematic review of Profhilo and Profhilo Body.
A systematic review brings together available evidence, but it does not automatically resolve the methodological limitations of the underlying studies.
Evidence from an individual facial Profhilo study
A prospective, open-label study involving 30 Chinese women evaluated Profhilo following two facial treatments administered four weeks apart.
Participants were followed through Week 12.
The researchers reported statistically significant improvements in superficial skin hydration and transepidermal water loss at Week 12 compared with baseline.
However, hydration measurements at that assessment were available for only six participants.
Changes in wrinkle-severity and facial-volume-loss scores were observed over time, but the individual time-point comparisons were not statistically significant.
Certain elasticity-related findings were also less conclusive.
These distinctions are important.
An improvement in a measured hydration parameter does not establish an equally reliable effect on structural facial volume, lifting or every elasticity-related outcome.
The study was small, did not include a control group and was not designed to establish comparative superiority over SKINVIVE.
The original research is available in Efficacy and Tolerability of Stable Hybrid Cooperative Complexes of High- and Low-Molecular Weight Hyaluronic Acid in Asian Patients.
Is There Evidence That One Treatment Works Better?
The literature reviewed for this article did not establish robust direct head-to-head evidence demonstrating that SKINVIVE is universally more effective than Profhilo, or vice versa.
The principal SKINVIVE studies and the available Profhilo studies differ in several ways:
- Clinical endpoints and measurement scales.
- Patient populations.
- Anatomical treatment areas.
- Product quantities and administration protocols.
- Study design and follow-up intervals.
A percentage improvement in cheek smoothness cannot be directly compared with a change in superficial hydration or elasticity measured in a separate trial.
Likewise, the presence of a US FDA indication for one product does not establish that it is universally superior to another product across every skin-quality concern.
The clinically meaningful question is which treatment has relevant evidence for the specific concern being assessed.
That distinction is more useful than interpreting promotional claims about glow, tightening, bioremodelling or collagen stimulation as interchangeable clinical outcomes.
How Long Do SKINVIVE and Profhilo Results Last?
When comparing SKINVIVE vs Profhilo longevity, it is important to distinguish the duration demonstrated in clinical research from recommended maintenance intervals.
These are not necessarily equivalent.
How Long Does SKINVIVE Last?
In the study supporting its original US cheek-smoothness approval, 55.6% of treated participants with evaluable data at six months continued to meet the defined response threshold.
This provides a clinically supported six-month reference point for that particular indication.
It does not guarantee that every patient experiences an identical degree or duration of improvement.
The separate neck-line study also reported six-month response data, but its endpoint and study population differed from those of the cheek-smoothness trial.
The two indications should therefore be interpreted independently.
How Long Does Profhilo Last?
Profhilo’s reported duration varies according to the formulation, study design, outcome measured and follow-up period.
For example, the cited prospective facial study evaluated outcomes through Week 12 after an initial two-session protocol.
This supports conclusions about the findings observed during that follow-up period. It does not establish that every benefit persists for nine or twelve months.
Other studies have used different follow-up intervals.
Maintenance recommendations should not be treated as proof of an identical treatment duration for every patient.
Neither product should be assigned a universal longevity figure by comparing unrelated clinical studies.
Further treatment should be considered according to individual assessment and the applicable product protocol.
SKINVIVE vs Profhilo Cost in India
When comparing the SKINVIVE vs Profhilo price, the financial commitment of an initial treatment course is often more informative than the price of one appointment.
The number of sessions, anatomical area, product quantity and need for additional treatment can influence the total cost.
At The Face Clinic, Hauz Khas, the currently published prices provide the following reference.
Cost consideration | SKINVIVE | Profhilo |
Published price per session | ₹25,000–₹35,000 | Starting at ₹40,000 |
Common initial treatment structure | May involve one session | Commonly two sessions approximately four weeks apart |
Illustrative initial-course cost | ₹25,000–₹35,000 if one session is sufficient | Approximately ₹80,000 for two sessions |
Additional treatment | Published top-up starting at ₹15,000, if indicated | According to the individual treatment plan |
Consultation | Included in the published initial-session offering | Confirm inclusion with the clinic |
Maintenance | Individualised | Individualised |
Why Should the Initial Course Be Compared Rather Than Individual Sessions?
A patient may initially interpret a lower per-session price as a lower overall treatment commitment.
However, different starting protocols can involve different numbers of appointments.
For example, if one SKINVIVE session is clinically appropriate, the initial expenditure may differ substantially from a commonly used two-session Profhilo facial course.
This does not establish that both treatment plans cover identical anatomical areas, use equivalent product quantities or produce interchangeable outcomes.
Likewise, a higher treatment cost does not independently establish greater clinical effectiveness.
A quotation should identify the treatment area, product quantity, number of sessions, possible additional treatment and any separately applicable charges.
For current product-specific information, see the dedicated SKINVIVE treatment cost and details and Profhilo treatment cost and details pages.
The relevant financial comparison is between the actual treatment plans proposed for the individual patient—not simply the two advertised session prices.
Safety, Side Effects and Contraindications
Both SKINVIVE and Profhilo are injectable medical treatments.
Neither should be described as universally safe, entirely free from complications or appropriate for every patient.
Potential adverse effects depend on the product, anatomical area, injection technique and individual medical considerations.
Common Injection-Site Reactions
Temporary reactions may include redness, tenderness, swelling, bruising, localised raised areas or injection-site bumps.
SKINVIVE may also produce firmness, itching or other local reactions described in its product information.
Profhilo may produce temporarily visible elevations at selected injection points.
The severity and duration of these reactions vary.
Persistent, worsening or unexpected symptoms require appropriate medical assessment.
Less Common but Important Complications
Injectable hyaluronic acid procedures can also be associated with infection, inflammatory reactions, nodules and allergic responses.
Unintentional injection of filler material into a blood vessel is an uncommon but potentially serious complication.
For dermal fillers, the US FDA identifies serious vascular complications including tissue necrosis, visual impairment and, rarely, stroke.
These risks are explained in the FDA’s dermal filler safety information.
General filler safety guidance should not be interpreted as establishing identical complication frequencies for SKINVIVE and Profhilo.
Appropriate comparative evidence would be needed to establish whether one product has a lower risk of a particular complication.
Urgent warning signs: Unusual or severe pain, blanching or discolouration of the skin, visual disturbance or neurological symptoms during or after an injectable procedure require immediate medical assessment. Sudden visual or neurological symptoms warrant emergency care.
When May Treatment Be Unsuitable?
Before treatment, the medical assessment should consider:
- Previous severe allergic reactions and relevant product-component allergies.
- Active infection or inflammation in the proposed treatment area.
- Previous injectable treatments and any associated complications.
- Relevant medical conditions and medications.
- Pregnancy or breastfeeding, where adequate safety information may be unavailable.
- Product-specific contraindications and precautions.
The original US SKINVIVE documentation identifies contraindications including severe allergies involving anaphylaxis or multiple severe allergies, sensitivity to gram-positive bacterial proteins and allergy to lidocaine.
Profhilo suitability must be evaluated against the current instructions for the specific formulation being administered.
The contraindications of one treatment should not automatically be assumed to be identical to those of the other.
An appropriately qualified practitioner should explain the relevant benefits, limitations, alternatives and risks before proceeding.
Can SKINVIVE and Profhilo Be Combined?
SKINVIVE and Profhilo have overlapping skin-quality applications, but their different formulations do not automatically justify combining them.
Some patients may present with several concurrent concerns, such as uneven skin smoothness, reduced hydration and changes in elasticity.
However, identifying multiple concerns is not sufficient reason to administer both products.
Before considering combination treatment, the clinician should establish whether each product has a distinct objective, whether the proposed anatomical areas and timing are appropriate, and whether the anticipated benefit justifies the additional procedure.
Previous treatment history, contraindications and relevant product instructions must also be considered.
Robust evidence establishing that a routine SKINVIVE–Profhilo combination produces superior outcomes compared with appropriately selected individual treatment was not identified in the literature reviewed for this article.
This does not establish that every combination approach is ineffective.
It means that combining the products should not be presented as a standard protocol, necessary upgrade or guaranteed way to improve results.
Treatment selection should remain individualised, whether one product, both products or neither is considered appropriate.
How Is Treatment Suitability Assessed?
The question of SKINVIVE or Profhilo cannot be answered reliably by age, skin type or preference for one brand alone.
Clinical assessment begins by identifying the specific concern and understanding which changes are contributing to it.
At The Face Clinic, relevant considerations include skin surface and texture, hydration, elasticity, underlying facial volume, anatomical treatment area, medical history and previous procedures.
An appropriate evaluation also considers the patient’s treatment preferences, potential downtime, financial commitment and the limitations of the available evidence.
A Clinical Distinction That Matters
Patients frequently describe different concerns using similar expressions, such as dullness, tired-looking skin or facial ageing.
These descriptions do not necessarily identify the underlying tissue-level problem.
Uneven skin smoothness, reduced hydration, changes in elasticity and loss of facial support require different clinical considerations.
A product selected to address one objective should not automatically be expected to correct the others.
For example, a patient may have reduced skin hydration alongside significant cheek-volume loss. Improving skin hydration does not necessarily correct the deeper volume deficit.
Likewise, an improvement in an elasticity-related measurement should not automatically be interpreted as structural lifting.
For this reason, meaningful treatment planning begins with examination of the skin and underlying facial anatomy rather than simply selecting a product according to its advertised benefits.
Does Indian Skin Require a Different Treatment Approach?
Indian patients represent a wide range of skin tones, skin characteristics and aesthetic concerns.
Treatment suitability should therefore not be determined by ethnicity or skin colour alone.
Individual factors—including skin condition, previous treatments, pigmentation concerns, medical history and facial anatomy—are relevant to clinical assessment.
Profhilo has been investigated in Asian populations, including the cited study involving Chinese women. However, findings from a small study should not automatically be generalised to every Indian patient.
Similarly, the availability of SKINVIVE clinical evidence does not establish that every individual will experience an equivalent response.
Patients with a history of post-inflammatory pigmentation or other skin reactions should discuss those concerns during assessment.
The relevant consideration is the individual’s clinical presentation and the evidence supporting the intended treatment objective—not an assumption that one product is universally more suitable for Indian skin.
At The Face Clinic, Dr. Reema Arora’s doctor-led assessment is intended to determine whether either injectable skin-quality treatment addresses the patient’s concern.
An appropriate recommendation may involve SKINVIVE, Profhilo, another treatment category or no injectable intervention.
The objective is to identify a clinically suitable approach, not to ensure that one of the two products is selected.
Frequently Asked Questions
What Is the Main Difference Between SKINVIVE and Profhilo?
SKINVIVE is a cross-linked hyaluronic acid dermal filler with defined US FDA indications for cheek skin smoothness and neck-line reduction. Profhilo contains stabilised hybrid cooperative complexes of hyaluronic acid and has been investigated for several aspects of skin quality.
Their formulations, supporting evidence and commonly used treatment protocols differ.
Is SKINVIVE or Profhilo Better for Skin Hydration?
Both products have skin-quality applications involving hydration, but their supporting studies evaluate different outcomes.
The available evidence does not establish that either product provides universally superior hydration results.
Clinical suitability depends on the specific concern, treatment area and individual characteristics.
Is Profhilo Better for Sagging Skin?
Profhilo has been investigated for aspects of skin quality, including certain elasticity- and laxity-related measures.
However, improvement in these parameters does not automatically establish meaningful lifting of descended facial tissues.
Significant sagging requires assessment of the underlying structural concern.
Is SKINVIVE a Dermal Filler?
Yes. SKINVIVE is classified as a hyaluronic acid dermal filler.
Its principal skin-smoothness applications differ from conventional volumising fillers used for structural facial augmentation.
It should not be described as containing no filler material or having absolutely no volume-related tissue effect.
What Should You Look for in SKINVIVE vs Profhilo Reviews?
Patient reviews may provide information about treatment experience, recovery and satisfaction, but they cannot independently establish comparative clinical superiority.
When reading SKINVIVE vs Profhilo reviews, consider the treatment area, initial skin condition, number of sessions and timing of the assessment.
Before-and-after photographs should also be evaluated for differences in lighting, facial expression, camera position and treatment timing.
Individual experiences are not substitutes for product-specific clinical evidence.
Which Treatment Lasts Longer: SKINVIVE or Profhilo?
The original SKINVIVE cheek-smoothness study demonstrated improvement in a defined proportion of treated participants through six months.
Profhilo studies have evaluated different outcomes over varying follow-up periods.
These findings do not establish that either treatment consistently lasts longer than the other across all patients and treatment areas.
Can SKINVIVE and Profhilo Be Used on the Neck?
SKINVIVE received a separate US FDA indication in June 2026 for reducing neck lines to improve neck appearance in adults over 21.
Profhilo and related formulations have also been investigated for neck skin-quality concerns.
The specific product, applicable local indications, clinical evidence and individual anatomy must guide treatment decisions.
What Is the Difference Between SKINVIVE and Profhilo Price in India?
At The Face Clinic, the currently published SKINVIVE price is ₹25,000–₹35,000 per session, while Profhilo starts at ₹40,000 per session.
A commonly used two-session Profhilo facial course would therefore be approximately ₹80,000.
Final pricing depends on product quantity, treatment area, number of appointments and individual requirements.
These are The Face Clinic’s published figures, not national market averages.
Do SKINVIVE and Profhilo Replace Conventional Volumising Fillers?
Neither is primarily intended for structural facial augmentation.
Although SKINVIVE belongs to the dermal filler category, its specified skin-smoothness applications differ from conventional fillers used to restore volume or create projection.
Profhilo is also primarily associated with skin-quality applications rather than structural contouring.
Can You Have SKINVIVE After Profhilo, or Profhilo After SKINVIVE?
Previous treatment with one product does not automatically establish that the other is appropriate.
The practitioner must consider the treatment area, timing, previous response, any complications and the intended clinical objective.
There is no universal sequence or interval that should be recommended without individual assessment and consideration of applicable product instructions.
How Far in Advance of an Important Event Should Treatment Be Planned?
Neither SKINVIVE nor Profhilo should be treated as a guaranteed last-minute procedure.
Injection-site reactions can occur with either treatment, and the time needed to assess the clinical response differs between protocols.
Profhilo commonly involves an initial course spread across approximately four weeks, while SKINVIVE may involve one initial session with additional treatment when indicated.
Patients planning treatment before an important event should discuss scheduling, possible downtime and follow-up requirements with their treating practitioner.
Discuss Skin-Quality Treatment Options at The Face Clinic
Understanding the differences between SKINVIVE and Profhilo can help you make an informed decision. The more important clinical question is whether either treatment addresses the specific concern you wish to improve.
At The Face Clinic in Hauz Khas, New Delhi, Dr. Reema Arora evaluates skin quality, facial anatomy, previous treatments and individual goals before discussing suitable options.
With over 20 years of experience in facial aesthetics, including advanced injectable training and clinical education, Dr. Arora brings a doctor-led perspective to treatment planning.
A consultation provides an opportunity to discuss the relevant clinical evidence, expected treatment course, limitations, potential risks and costs—without assuming that either product is necessarily indicated.
The Face Clinic — Dr. Reema Arora C-36, Lower Ground Floor Hauz Khas Market New Delhi – 110016, India
Clinic hours: Monday–Saturday, 10 AM–6 PM Telephone: +91 99580 73900
Enquire about a skin-quality consultation
Treatment recommendations are subject to individual medical assessment. Results vary, and no particular outcome can be guaranteed.
